^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER
Excerpt:
Amgen...announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after systemic anticancer therapy.
Source:
Title:
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Excerpt:
...patients must have KRAS p.G12C molecularly confirmed previously or have archived tissue sent for testing and/or undergo biopsy confirming KRAS p.G12C mutation prior to enrollment....
Trial ID:
Source:
Title:
First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety
Published date:
02/17/2022
Excerpt:
Eight patients had confirmed partial response by BICR with a resulting ORR of 21.1% (95% CI: 9.55%-37.32%). DCR was 84.2%....Sotorasib demonstrated clinically meaningful anticancer activity and tolerability in patients with heavily pretreated KRASG12C-mutated advanced pancreatic cancer, who have limited treatment options and poor prognosis.
DOI:
10.1200/JCO.2022.40.36_suppl.360490
Trial ID:
Source:
Title:
LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL
Published date:
02/14/2022
Excerpt:
Amgen...announced the presentation of efficacy and safety data from the CodeBreaK 100 Phase 1/2 trial in patients with KRAS G12C-mutated advanced pancreatic cancer who received LUMAKRAS® (sotorasib)...LUMAKRAS demonstrated a centrally confirmed objective response rate (ORR) of 21% and disease control rate (DCR) of 84% across 38 heavily pre-treated advanced pancreatic cancer patients... The results also show a median progression free survival (PFS) of 4 months and a median overall survival (OS) of almost 7 months.
Source:
Title:
83MO - AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial
Published date:
11/17/2020
Excerpt:
At 960mg, ORR and DCR were 12.0% (3/25) and 80.0% (20/25). 15 of 17 pts with other GI cancers were evaluable: 1 confirmed partial response (appendiceal), 9 stable disease (6 pancreatic, 2 appendiceal, and 1 bile duct), and 5 progressive disease. 3 pts with pancreatic cancer achieving stable disease had the best tumor burden reduction of 28.0%, 28.9%, and 31.6% from baseline, respectively. In pts with heavily pretreated KRAS p.G12C mutant GI cancers, AMG 510 was well tolerated, with the majority of pts achieving disease control.
Trial ID:
Source:
Title:
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Published date:
09/20/2020
Excerpt:
We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation….Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma….Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation.
DOI:
10.1056/NEJMoa1917239
Trial ID:
Source:
Title:
Radiation combined with KRAS-MEK inhibitors enhances anticancer immunity in KRAS-mutated tumor models
Published date:
08/06/2022
Excerpt:
...we investigated the additive effect of radiation and KRAS-MEK inhibitors (AMG510 and trametinib) in KRAS-mutated tumors....The four human cancer cell lines with the KRAS G12C mutation had different sensitivities to AMG510, and the CCK-8 assay showed that miapaca2 and H358 cells were more sensitive to AMG510 than the other cell lines (Figure 1B) and were also sensitive to MEKi...
DOI:
https://doi.org/10.1016/j.trsl.2022.08.005
